Pharmaceutical Regulatory Affairs: Open Access

Department of Hematology, Medical School, National and Kapodistrian University of Athens, “Laiko” General Hospital, 11527 Athens, Greece

Publications

• Mini Review   
  Pharmacological Control and Protection against Cardiotoxicity in Blood Cancer
  Author(s): Almeida Michele*
  
  Clinical outcomes of patients with hematological malignancies have been improved by current hematology treatment options. Also, many new or old anticancer drugs affect the cardiovascular system, causing heart problems like left ventricular failure, cardiovascular breakdown, blood vessel hypertension, myocardial ischemia, cardiovascular musicality problems and QTc prolongation on electrocardiograms. It is essential to become familiar with all aspects of cardiotoxicity and to immediately give these patients the proper consideration because these misunderstandings could jeopardize the substantially improved outcomes of current anticancer treatments. In a similar vein, new and established medications contribute to both primary and secondary prevention of cardiovascular infections. Patients with hematologic malignancies undergoing anticancer medication treatment or .. Read More»
  DOI: 10.37421/2167-7689.2022.11.344

  Abstract HTML PDF